ResMed Inc.RMDNYSE
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank62
3Y CAGR-26.7%
5Y CAGR+41.5%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-26.7%/yr
Quarterly compound
5Y CAGR
+41.5%/yr
Recent deceleration
Percentile
P62
Within normal range
vs 5Y Ago
5.7x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 4.18% |
| Q3 2025 | 1.02% |
| Q2 2025 | 2.98% |
| Q1 2025 | 3.16% |
| Q4 2024 | 2.33% |
| Q3 2024 | -1.65% |
| Q2 2024 | 4.91% |
| Q1 2024 | 4.32% |
| Q4 2023 | -2.42% |
| Q3 2023 | -3.11% |
| Q2 2023 | 2.23% |
| Q1 2023 | 9.39% |
| Q4 2022 | 10.58% |
| Q3 2022 | -1.76% |
| Q2 2022 | -3.72% |
| Q1 2022 | 6.87% |
| Q4 2021 | 4.27% |
| Q3 2021 | 0.13% |
| Q2 2021 | 7.03% |
| Q1 2021 | 1.83% |
| Q4 2020 | 0.74% |
| Q3 2020 | 3.83% |
| Q2 2020 | 2.08% |
| Q1 2020 | 3.02% |
| Q4 2019 | 3.98% |
| Q3 2019 | -6.07% |
| Q2 2019 | 7.41% |
| Q1 2019 | 10.44% |
| Q4 2018 | 11.14% |
| Q3 2018 | -2.18% |
| Q2 2018 | 5.94% |
| Q1 2018 | -7.90% |
| Q4 2017 | 8.63% |
| Q3 2017 | 1.93% |
| Q2 2017 | 4.49% |
| Q1 2017 | -8.01% |
| Q4 2016 | 10.87% |
| Q3 2016 | 0.19% |
| Q2 2016 | 22.31% |
| Q1 2016 | -2.97% |